A Step-by-Step Guide to Developing a Robust Assay in Bioanalysis Using LC-MS/MS

LC-MS/MS assay development within Bioanalysis is driven by developing accurate, precise and robust methods within the shortest time frame possible.

Within our department we have employed a generic protocol to enable a consistent and efficient process to reach these goals.

LC-MS/MS Conditions

Initial Screening

Determine: Log D and pKa to assist in initial decision making

Infusion of analyte into MS

  • Pos/Neg, ESI/APCI
  • M+H or M-H or Adducts
  • Minimise adducts or maximise

Scouting HPLC Gradients

  • Acidic & Basic & buffered mobile phases for retention and signal:noise (S:N)
  • Gradient for sharper peaks and sensitivity
  • Isocratic for resolution

 

 

 

Limit of Quantitation

  • Dilution series made in solution
  • Provides an idea of what sort of sample extraction technique is needed
  • S:N of 20:1 to enable an ↑chance it will be suitable in matrix

 

Carryover

If observed will need to locate the source: 

 

 

 

Sample Extraction

Binding

Non-specific Binding

Binding test performed as follows in 3 types of materials:

  • Glass
  • Polypropylene
  • Polyethylene

Analyte 1

Analyte 2

Binding in Urine

Conclusion

Utilising this generic guide as a starting point for method development of each new compound streamlined our processes and highlights issues at an early stage and creates a solid basis for future troubleshooting.

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.